

CONTENTS

NOTE TO THE READER	1
LIST OF PARTICIPANTS	3
PREAMBLE	9
A. GENERAL PRINCIPLES AND PROCEDURES	9
1. Background.....	9
2. Objective and scope.....	10
3. Selection of agents for review.....	11
4. Data for the <i>Monographs</i>	12
5. Meeting participants.....	12
6. Working procedures.....	13
B. SCIENTIFIC REVIEW AND EVALUATION	14
1. Exposure data.....	15
2. Studies of cancer in humans.....	16
3. Studies of cancer in experimental animals.....	20
4. Mechanistic and other relevant data.....	23
5. Summary.....	26
6. Evaluation and rationale.....	27
References.....	31
GENERAL REMARKS	33
CARBON NANOTUBES	35
1. Exposure Data.....	35
1.1 Chemical and physical properties.....	35
1.2 Sampling and analytical methods.....	45
1.3 Production and use.....	49
1.4 Occurrence and exposure.....	51
1.5 Regulations and guidelines.....	64
2. Cancer in Humans.....	66

3. Cancer in Experimental Animals	66
3.1 MWCNT	66
3.2 SWCNT	72
4. Mechanistic and Other Relevant Data	74
4.1 Deposition, phagocytosis, translocation, retention, and clearance	74
4.2 Physico-chemical properties associated with toxicity	90
4.3 Genetic and related effects	100
4.4 Other mechanisms of carcinogenesis	120
4.5 Susceptible populations	170
4.6 Mechanistic considerations	177
5. Summary of Data Reported	189
5.1 Exposure data	189
5.2 Human carcinogenicity data	190
5.3 Animal carcinogenicity data	190
5.4 Mechanistic and other relevant data	190
6. Evaluation	192
6.1 Cancer in humans	192
6.2 Cancer in experimental animals	192
6.3 Overall evaluation	192
References	192
FLUORO-EDENITE	215
1. Exposure Data	215
1.1 Chemical and physical properties	215
1.2 Sampling and analytical methods	219
1.3 Production and use	220
1.4 Environmental occurrence	220
1.5 Exposure of the general population	222
2. Cancer in Humans	222
2.1 Introduction	222
2.2 Mesothelioma	222
2.3 Cancer of the lung	224
2.4 Other neoplasms	227
3. Cancer in Experimental Animals	228
4. Mechanistic and Other Relevant Data	230
4.1 Deposition, phagocytosis, retention, translocation, and clearance	230
4.2 Physico-chemical properties associated with toxicity	232
4.3 Genetic and related effects	234
4.4 Other mechanistic data relevant to carcinogenesis	234
4.5 Susceptible populations	238
4.6 Mechanistic considerations	238
5. Summary of Data Reported	238
5.1 Exposure data	238
5.2 Human carcinogenicity data	238
5.3 Animal carcinogenicity data	239
5.4 Mechanistic and other relevant data	239

6. Evaluation.....	239
6.1 Cancer in humans.....	239
6.2 Cancer in experimental animals.....	239
6.3 Overall evaluation.....	239
References.....	240
SILICON CARBIDE.....	243
1. Exposure Data.....	243
1.1 Chemical and physical properties.....	243
1.2 Sampling and analytical methods.....	247
1.3 Production and use.....	248
1.4 Natural occurrence.....	254
1.5 Exposure.....	255
1.6 Regulations and guidelines.....	261
2. Cancer in Humans.....	262
2.1 Introduction.....	262
2.2 Silicon-carbide production industry.....	263
2.3 Silicon-carbide user industry.....	267
3. Cancer in Experimental Animals.....	267
3.1 Inhalation.....	267
3.2 Intratracheal instillation.....	270
3.3 Intrapleural implantation.....	270
3.4 Intraperitoneal injection.....	271
4. Mechanistic and Other Relevant Data.....	272
4.1 Deposition, phagocytosis, retention, translocation, and clearance.....	272
4.2 Physico-chemical properties associated with toxicity.....	284
4.3 Genetic and related effects.....	294
4.4 Other mechanisms of carcinogenesis.....	296
4.5 Susceptible populations.....	302
4.6 Mechanistic considerations.....	302
5. Summary of Data Reported.....	302
5.1 Exposure data.....	302
5.2 Human carcinogenicity data.....	303
5.3 Animal carcinogenicity data.....	304
5.4 Mechanistic and other relevant data.....	304
6. Evaluation.....	305
6.1 Cancer in humans.....	305
6.2 Cancer in experimental animals.....	305
6.3 Overall evaluation.....	305
6.4 Rationale.....	305
References.....	306
LIST OF ABBREVIATIONS.....	315

NOTE TO THE READER

The term ‘carcinogenic risk’ in the *IARC Monographs* series is taken to mean that an agent is capable of causing cancer. The *Monographs* evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the *Monographs* does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a *Monograph* does not mean that it is not carcinogenic. Similarly, identification of cancer sites with *sufficient evidence* or *limited evidence* in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the *Monographs* as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.